23 May 2018 - - Horsham, Pennsylvania-based Janssen Pharmaceutical Companies, a segment of US-based global healthcare company Johnson and Johnson (NYSE: JNJ) has presented a post-hoc analysis from the Phase 3 SPARTAN study at the 2018 American Urological Association (AUA) annual meeting, the company said.
Data showed that treatment with Erleada (apalutamide) significantly reduced the risk of prostate specific antigen (PSA) progression in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who had a rapidly rising PSA while receiving continuous androgen deprivation therapy.
Janssen also presented results of a population-based study of PSA doubling time in patients with nmCRPC that assessed the association between PSA doubling time and both metastasis-free survival and overall survival. Shorter PSA doubling time has been associated with shorter time to metastasis or death.
Erleada (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with nmCRPC.
The Janssen Pharmaceutical Companies of Johnson and Johnson work to find new and better ways to prevent, intercept, treat, and cure disease. The pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases.